drugset
Drugs / tenofovir alfenamide
last change Dec 2024 re-read 2 minutes ago

tenofovir alfenamide

also known as TAF
Developed for
HIV infectious disease
Investigated by
CONRAD · Centre Hospitalier Universitaire Vaudois · EuroVacc Foundation · Gilead Sciences · Imperial College London · Instituto Nacional de Saúde, Mozambique
+9 more · International AIDS Vaccine Initiative · Karolinska Institutet · King's College London · Ludwig-Maximilians - University of Munich · MRC/UVRI and LSHTM Uganda Research Unit · Medical Research Council, South Africa · Muhimbili University of Health and Allied Sciences · National Institute for Medical Research, Tanzania · University College, London

Trials 1 · a red edge is where a trial was stopped

today NCT04066881 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04066881 Dec 2020 → Dec 2024 HIV infectious disease MRC/UVRI and LSHTM Uganda Research Unit Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as tenofovir alfenamide “Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC)” NCT04066881 ↗
Known as TAF “Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC)” NCT04066881 ↗